Patients are usually affected by Multiple sclerosis at a highly productive stage of life, when people are building careers and planning families. MS can have a significant impact on affected individuals as much as their families and society.

According to National Multiple sclerosis (MS) Society study estimate, about one million people in the U.S are affected by Multiple sclerosis, which is much higher than the first national research on MS prevalence since 1975 and the last reported number. Also has been reported that 2.3 million people live with Multiple sclerosis worldwide and about 200 new cases are being diagnosed each week in the US.

Although there is a lack of ultimate cure for Multiple sclerosis, but our growing knowledge in disease-modifying therapies can make an opportunity for patients to reduce disability and extend chance of survival.

Hence, one of Parsian’s fields of activity is research and development in Multiple sclerosis to manufacture active pharmaceutical ingredients (API) and Granules of Multiple sclerosis medicines with the highest global standards to help patients having Multiple sclerosis to be cured in a better way by the latest guidelines and with the lowest adverse effects.